SG11202102727RA - Immunoproteasome inhibitor formulation - Google Patents
Immunoproteasome inhibitor formulationInfo
- Publication number
- SG11202102727RA SG11202102727RA SG11202102727RA SG11202102727RA SG11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA SG 11202102727R A SG11202102727R A SG 11202102727RA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitor formulation
- immunoproteasome inhibitor
- immunoproteasome
- formulation
- inhibitor
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 229940126097 immunoproteasome inhibitor Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862741221P | 2018-10-04 | 2018-10-04 | |
PCT/US2019/054605 WO2020072848A1 (en) | 2018-10-04 | 2019-10-04 | Immunoproteasome inhibitor formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202102727RA true SG11202102727RA (en) | 2021-04-29 |
Family
ID=68296831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202102727RA SG11202102727RA (en) | 2018-10-04 | 2019-10-04 | Immunoproteasome inhibitor formulation |
Country Status (16)
Country | Link |
---|---|
US (1) | US20220040192A1 (en) |
EP (1) | EP3860574A1 (en) |
JP (1) | JP2022501404A (en) |
KR (1) | KR20210071982A (en) |
CN (2) | CN113164397A (en) |
AU (1) | AU2019355041A1 (en) |
BR (1) | BR112021006339A2 (en) |
CA (1) | CA3113530A1 (en) |
CL (1) | CL2021000832A1 (en) |
CO (1) | CO2021004990A2 (en) |
MX (1) | MX2021003899A (en) |
PE (1) | PE20211817A1 (en) |
PH (1) | PH12021550717A1 (en) |
SG (1) | SG11202102727RA (en) |
TW (1) | TWI827694B (en) |
WO (1) | WO2020072848A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118255835A (en) * | 2022-12-27 | 2024-06-28 | 上海美悦生物科技发展有限公司 | Tripeptide epoxy ketone compound, pharmaceutical composition, preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095426A1 (en) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE |
RU2017115193A (en) * | 2014-10-01 | 2018-11-06 | Мерк Патент Гмбх | Derivatives of Boronic Acid |
HRP20230533T1 (en) * | 2016-06-29 | 2023-08-04 | Kezar Life Sciences | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor |
-
2019
- 2019-10-04 KR KR1020217009893A patent/KR20210071982A/en active Search and Examination
- 2019-10-04 AU AU2019355041A patent/AU2019355041A1/en active Pending
- 2019-10-04 WO PCT/US2019/054605 patent/WO2020072848A1/en active Application Filing
- 2019-10-04 BR BR112021006339A patent/BR112021006339A2/en unknown
- 2019-10-04 PE PE2021000445A patent/PE20211817A1/en unknown
- 2019-10-04 CA CA3113530A patent/CA3113530A1/en active Pending
- 2019-10-04 SG SG11202102727RA patent/SG11202102727RA/en unknown
- 2019-10-04 TW TW108135985A patent/TWI827694B/en active
- 2019-10-04 CN CN201980065552.1A patent/CN113164397A/en active Pending
- 2019-10-04 MX MX2021003899A patent/MX2021003899A/en unknown
- 2019-10-04 US US17/281,404 patent/US20220040192A1/en active Pending
- 2019-10-04 EP EP19791110.0A patent/EP3860574A1/en active Pending
- 2019-10-04 CN CN202310863235.2A patent/CN116983271A/en active Pending
- 2019-10-04 JP JP2021517595A patent/JP2022501404A/en active Pending
-
2021
- 2021-03-30 PH PH12021550717A patent/PH12021550717A1/en unknown
- 2021-04-01 CL CL2021000832A patent/CL2021000832A1/en unknown
- 2021-04-19 CO CONC2021/0004990A patent/CO2021004990A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022501404A (en) | 2022-01-06 |
KR20210071982A (en) | 2021-06-16 |
EP3860574A1 (en) | 2021-08-11 |
TW202027729A (en) | 2020-08-01 |
CL2021000832A1 (en) | 2021-10-22 |
PH12021550717A1 (en) | 2021-11-03 |
AU2019355041A1 (en) | 2021-04-15 |
CN113164397A (en) | 2021-07-23 |
WO2020072848A1 (en) | 2020-04-09 |
US20220040192A1 (en) | 2022-02-10 |
CA3113530A1 (en) | 2020-04-09 |
CN116983271A (en) | 2023-11-03 |
CO2021004990A2 (en) | 2021-04-30 |
MX2021003899A (en) | 2021-06-04 |
PE20211817A1 (en) | 2021-09-14 |
TWI827694B (en) | 2024-01-01 |
BR112021006339A2 (en) | 2021-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283639A (en) | Kif18a inhibitors | |
IL277006A (en) | Cd73 inhibitors | |
PT3626699T (en) | Ssao inhibitor | |
IL304348A (en) | Cd73 inhibitors | |
GB201705971D0 (en) | Inhibitor compounds | |
IL274523A (en) | Immunoproteasome inhibitors | |
GB201819126D0 (en) | Inhibitor compounds | |
IL276013A (en) | Pi4kiiibeta inhibitors | |
SI3571208T1 (en) | Immunoproteasome inhibitors | |
IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
SI3710457T1 (en) | Immunoproteasome inhibitors | |
SG11202102727RA (en) | Immunoproteasome inhibitor formulation | |
PL3606515T3 (en) | Stat3 inhibitor formulation | |
GB201809939D0 (en) | Eastase inhibitor | |
GB201812462D0 (en) | Inhibitors | |
GB201819136D0 (en) | Inhibitor compounds | |
GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
GB201806131D0 (en) | Inhibitor compounds | |
GB201806130D0 (en) | Inhibitor compounds | |
EP3426641A4 (en) | Immunoproteasome inhibitor analogs | |
GB201720145D0 (en) | Inhibitor compounds | |
GB201708510D0 (en) | Inhibitor compounds | |
GB201708507D0 (en) | Inhibitor compounds | |
GB201708502D0 (en) | Inhibitor compounds | |
GB201705968D0 (en) | Inhibitor compounds |